Mauro Gori
Overview
Explore the profile of Mauro Gori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
936
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fazzini L, Padkins M, Berg-Hansen K, Gori M, Kane G, Hillerson D, et al.
Eur Heart J Acute Cardiovasc Care
. 2025 Mar;
PMID: 40073196
Background: Left ventricular (LV) ventricular-arterial coupling (VAC) refers to the ratio of afterload (effective arterial elastance) to contractility (end-systolic elastance) as an integrated marker of cardiac performance. We sought to...
2.
Matassini M, Manca P, Limonta R, Marini M, Orso F, Carigi S, et al.
G Ital Cardiol (Rome)
. 2025 Feb;
26(3):173-184.
PMID: 39998347
Heart failure (HF) is a clinical syndrome with high morbidity and mortality, characterized by periods of relative clinical stability and exacerbations of HF, known as worsening heart failure (WHF). WHF...
3.
Cirelli C, Merlo A, Calabrese A, Fazzini L, Fiocca L, Senni M, et al.
J Clin Med
. 2025 Feb;
14(3).
PMID: 39941680
Mitral regurgitation (MR) is a common valvular disorder often seen in a severely dilated left ventricle (LV) and reduced LV function. In chronic heart failure (HF), severe functional MR increases...
4.
Tinti M, De Gennaro L, DElia E, Benvenuto M, Cittar M, Limonta R, et al.
G Ital Cardiol (Rome)
. 2024 Dec;
26(1):38-49.
PMID: 39714499
Mineralocorticoid receptor antagonists (MRAs) represent one of the cornerstones of treatment for heart failure with reduced ejection fraction. Post-hoc data from the TOPCAT trial, conducted in patients with heart failure...
5.
Wang X, Vardeny O, Claggett B, Vaduganathan M, Hegde S, Skali H, et al.
Eur J Heart Fail
. 2024 Dec;
27(1):96-106.
PMID: 39675788
Aims: To evaluate clinical outcomes, echocardiographic features, and the efficacy and safety of sacubitril/valsartan compared to valsartan across age groups in the PARAGON-HF trial. Methods And Results: A total of...
6.
Minneci C, Zucchini M, Gonzini L, Marini M, Gori M, De Maria R
Int J Cardiol
. 2024 Dec;
421():132906.
PMID: 39653314
Background: The role of hyperuricemia on short-term clinical prognosis in outpatients with heart failure and reduced ejection fraction (HFrEF) has few investigations and inconclusive results. We evaluated the prognostic impact...
7.
Mc Causland F, Vaduganathan M, Claggett B, Gori M, Jhund P, McGrath M, et al.
JACC Heart Fail
. 2024 Nov;
13(1):105-114.
PMID: 39570234
Background: Lower estimated glomerular filtration rate (eGFR) may be one of the major reasons for hesitation or failure to initiate potentially beneficial therapies in patients with heart failure (HF). Objectives:...
8.
Baldetti L, Gentile P, Gori M, Scandroglio A, Gasparetto N, Trambaiolo P, et al.
G Ital Cardiol (Rome)
. 2024 Sep;
25(9):624-639.
PMID: 39239814
More than 50 years after its introduction in clinical practice, the increase in the intensity of care offered by the cardiac intensive care units, the shift in the population of...
9.
Cirelli C, Limonta R, Carioli G, DElia E, Ameri P, Inciardi R, et al.
Eur J Intern Med
. 2024 Aug;
130:71-78.
PMID: 39117554
Background: Worsening Heart Failure (WHF) is associated with adverse prognosis. Identifying novel prognostic markers in WHF is crucial. Gait speed (GS), a validated frailty index, is an easily obtainable parameter...
10.
Fazzini L, Ghirardi A, Limonta R, Calabrese A, DElia E, Canova P, et al.
ESC Heart Fail
. 2024 Jul;
11(5):3350-3359.
PMID: 38965689
Aims: The identification of subjects at higher risk for incident heart failure (HF) with preserved ejection fraction (EF) suitable for more intensive preventive programmes remains challenging. We applied phenomapping to...